APA

Kümler I., Sørensen P. G., Palshof J., Høgdall E., Skovrider-Ruminski W., Theile S., Fullerton A., Nielsen P. G., Jensen B. V. & Nielsen D. L. (20191112). Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. : Cancer chemotherapy and pharmacology.

Chicago

Kümler I, Sørensen P Grundtvig, Palshof J, Høgdall E, Skovrider-Ruminski W, Theile S, Fullerton A, Nielsen P G, Jensen B Vittrup and Nielsen D L. 20191112. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. : Cancer chemotherapy and pharmacology.

Harvard

Kümler I., Sørensen P. G., Palshof J., Høgdall E., Skovrider-Ruminski W., Theile S., Fullerton A., Nielsen P. G., Jensen B. V. and Nielsen D. L. (20191112). Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. : Cancer chemotherapy and pharmacology.

MLA

Kümler I, Sørensen P Grundtvig, Palshof J, Høgdall E, Skovrider-Ruminski W, Theile S, Fullerton A, Nielsen P G, Jensen B Vittrup and Nielsen D L. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. : Cancer chemotherapy and pharmacology. 20191112.